Phase I trial of the tolerability, pharmacodynamics and pharmacokinetics of MK 2206 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2010
At a glance
- Drugs MK 2206 (Primary)
- Indications Breast cancer; Neuroendocrine tumours; Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Merck & Co
- 05 Nov 2010 New trial record.